Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTEC
CUSIPN/A
Phone972-2586-4657
Debt
Debt-to-Equity RatioN/A
Current Ratio8.25
Quick Ratio8.25
Price-To-Earnings
Trailing P/E Ratio-2.77
Forward P/E Ratio-3.63
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.26 per share
Price / Book2.02
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-29,090,000.00
Net MarginsN/A
Return on Equity-70.95%
Return on Assets-65.20%
Miscellaneous
Employees70
Outstanding Shares32,830,000
Market Cap$151.00
Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.13. View Intec Pharma's Earnings History.
When is Intec Pharma's next earnings date?
What price target have analysts set for NTEC?
6 brokers have issued twelve-month price targets for Intec Pharma's stock. Their forecasts range from $10.00 to $16.00. On average, they anticipate Intec Pharma's share price to reach $13.60 in the next year. This suggests a possible upside of 197.6% from the stock's current price. View Analyst Ratings for Intec Pharma.
What is the consensus analysts' recommendation for Intec Pharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Obseva (OBSV), Prothena (PRTA), Theratechnologies (THERF), CannTrust (CNTTF), Beyondspring (BYSI), Merus (MRUS), Akebia Therapeutics (AKBA), Insys Therapeutics (INSY), Arcus Biosciences (RCUS), Aduro BioTech (ADRO), TIGENIX/S (TIG), ArQule (ARQL), Keryx Biopharmaceuticals (KERX), Depomed (DEPO) and Lannett (LCI).
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- Mr. Nir Sassi, Chief Financial Officer (Age 42)
- Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 49)
- Mr. Zeev Weiss, Clinical and Bus. Devel. Consultant (Age 56)
- Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 51)
- Mr. Walt Addison Linscott Esq., Chief Admin. Officer (Age 57)
When did Intec Pharma IPO?
(NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.
Has Intec Pharma been receiving favorable news coverage?
Media stories about NTEC stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intec Pharma earned a daily sentiment score of 0.04 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 43.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Intec Pharma?
Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
One share of NTEC stock can currently be purchased for approximately $4.57.
How big of a company is Intec Pharma?
Intec Pharma has a market capitalization of $151 million. The biotechnology company earns $-29,090,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.
How can I contact Intec Pharma?
Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]
MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
